[
  {
    "ts": null,
    "headline": "Vertex Announces CASGEVY速 Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy",
    "summary": "LONDON, September 18, 2025--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY速 (exagamglogene autotemcel).",
    "url": "https://finnhub.io/api/news?id=ec9cf862baa4b77fa4b44636f496512b6bbf9ec243c7c9cd608f7b7bb4fb3070",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758202200,
      "headline": "Vertex Announces CASGEVY速 Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy",
      "id": 136797789,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "LONDON, September 18, 2025--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY速 (exagamglogene autotemcel).",
      "url": "https://finnhub.io/api/news?id=ec9cf862baa4b77fa4b44636f496512b6bbf9ec243c7c9cd608f7b7bb4fb3070"
    }
  }
]